|
Shenyang Xingqi Pharmaceutical Co., Ltd (300573.SZ) Avaliação DCF
CN | Healthcare | Medical - Instruments & Supplies | SHZ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) Bundle
Explore as perspectivas financeiras da Shenyang Xingqi Pharmaceutical Co., Ltd (300573SZ) com a nossa calculadora DCF amigável! Digite suas suposições sobre crescimento, margens e custos para calcular o valor intrínseco da Shenyang Xingqi Pharmaceutical Co., Ltd (300573SZ) e refine sua estratégia de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 542.4 | 688.7 | 1,027.9 | 1,249.9 | 1,467.6 | 1,890.3 | 2,434.9 | 3,136.3 | 4,039.8 | 5,203.6 |
| Revenue Growth, % | 0 | 26.96 | 49.26 | 21.59 | 17.42 | 28.81 | 28.81 | 28.81 | 28.81 | 28.81 |
| EBITDA | 84.1 | 157.8 | 323.9 | 315.5 | 355.2 | 451.4 | 581.4 | 748.9 | 964.6 | 1,242.5 |
| EBITDA, % | 15.51 | 22.92 | 31.51 | 25.24 | 24.21 | 23.88 | 23.88 | 23.88 | 23.88 | 23.88 |
| Depreciation | 43.7 | 48.9 | 73.5 | 80.0 | 88.8 | 131.4 | 169.2 | 218.0 | 280.7 | 361.6 |
| Depreciation, % | 8.05 | 7.09 | 7.15 | 6.4 | 6.05 | 6.95 | 6.95 | 6.95 | 6.95 | 6.95 |
| EBIT | 40.5 | 109.0 | 250.4 | 235.5 | 266.4 | 320.0 | 412.2 | 530.9 | 683.8 | 880.8 |
| EBIT, % | 7.46 | 15.83 | 24.36 | 18.84 | 18.15 | 16.93 | 16.93 | 16.93 | 16.93 | 16.93 |
| Total Cash | 50.0 | 37.2 | 686.4 | 515.4 | 480.4 | 587.4 | 756.6 | 974.5 | 1,255.3 | 1,616.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 130.4 | 158.2 | 182.6 | 195.0 | 252.1 | 368.8 | 475.1 | 611.9 | 788.2 | 1,015.3 |
| Account Receivables, % | 24.04 | 22.98 | 17.76 | 15.6 | 17.18 | 19.51 | 19.51 | 19.51 | 19.51 | 19.51 |
| Inventories | 79.9 | 68.3 | 92.3 | 122.3 | 136.0 | 199.2 | 256.5 | 330.4 | 425.6 | 548.2 |
| Inventories, % | 14.72 | 9.92 | 8.98 | 9.78 | 9.27 | 10.54 | 10.54 | 10.54 | 10.54 | 10.54 |
| Accounts Payable | 23.6 | 6.4 | 13.3 | 19.5 | 17.6 | 35.3 | 45.4 | 58.5 | 75.4 | 97.1 |
| Accounts Payable, % | 4.36 | 0.92479 | 1.3 | 1.56 | 1.2 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 |
| Capital Expenditure | -70.0 | -108.2 | -95.1 | -299.2 | -262.0 | -301.1 | -387.8 | -499.6 | -643.5 | -828.9 |
| Capital Expenditure, % | -12.9 | -15.7 | -9.25 | -23.94 | -17.85 | -15.93 | -15.93 | -15.93 | -15.93 | -15.93 |
| Tax Rate, % | 9.42 | 9.42 | 9.42 | 9.42 | 9.42 | 9.42 | 9.42 | 9.42 | 9.42 | 9.42 |
| EBITAT | 40.5 | 93.5 | 200.2 | 213.3 | 241.3 | 286.0 | 368.4 | 474.5 | 611.2 | 787.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -172.4 | .7 | 137.1 | -42.1 | -4.6 | -45.9 | -3.7 | -4.8 | -6.1 | -7.9 |
| WACC, % | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 | 5.33 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -62.0 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -8 | |||||||||
| Terminal Value | -617 | |||||||||
| Present Terminal Value | -476 | |||||||||
| Enterprise Value | -538 | |||||||||
| Net Debt | -408 | |||||||||
| Equity Value | -130 | |||||||||
| Diluted Shares Outstanding, MM | 124 | |||||||||
| Equity Value Per Share | -1.04 |
What You Will Receive
- Genuine 300573SZ Financials: Access to historical and projected data for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditure inputs.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess the future performance of Shenyang Xingqi Pharmaceutical Co., Ltd.
- User-Friendly and Professional Design: Tailored for experts while remaining easy to use for newcomers.
Key Features
- 🔍 Real-Life 300573SZ Financials: Pre-filled historical and projected data for Shenyang Xingqi Pharmaceutical Co., Ltd.
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) including WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas assess Shenyang Xingqi's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Shenyang Xingqi's valuation immediately after making adjustments.
- Scenario Analysis: Explore and compare outcomes for different financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for Shenyang Xingqi Pharmaceutical Co., Ltd (300573SZ) (historical and projected).
- Step 3: Modify key assumptions (yellow cells) based on your findings.
- Step 4: Observe automatic recalculations for the intrinsic value of Shenyang Xingqi Pharmaceutical Co., Ltd (300573SZ).
- Step 5: Utilize the results for investment decisions or reporting.
Why Opt for This Calculator?
- User-Friendly and Accessible: Suitable for both newcomers and seasoned users.
- Customizable Parameters: Adjust inputs easily to align with your analysis needs.
- Real-Time Updates: Observe immediate changes to Shenyang Xingqi Pharmaceutical's valuation as you modify inputs.
- Pre-Configured: Comes with Shenyang Xingqi Pharmaceutical's actual financial data for swift assessments.
- Relied Upon by Experts: Valued by investors and analysts for making well-informed decisions.
Who Can Benefit from Our Products?
- Pharmacy Students: Master pharmaceutical valuation methods and apply them using real-world data.
- Researchers: Integrate advanced models into your studies or academic projects.
- Investors: Validate your investment theories and analyze valuation results for Shenyang Xingqi Pharmaceutical (300573SZ).
- Market Analysts: Enhance efficiency with our ready-to-use, customizable DCF models.
- Entrepreneurs: Understand the analytical frameworks used for evaluating large pharmaceutical companies like Shenyang Xingqi (300573SZ).
What the Template Contains
- Preloaded SXP Data: Historical and projected financial information, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade spreadsheets for determining intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financials for extensive analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.